Secnidazole. A 5-nitroimidazole derivative with a long half-life.

Videau, D; Niel, Guillaume van; Siboulet, A; Catalán, F

doi:10.1136/sti.54.2.77

Cited by 24 publications

(25 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…vida media de eliminación terminal mayor (aproximadamente de 17 a 29 horas) que los medicamentos utilizados comúnmente en esta clase (28,29). Se comercializa para el tratamiento de la giardiasis en los seres humanos.…”

Section: 98%unclassified

See 1 more Smart Citation

Single dose of secnidazole treatment against naturally occuring Giardia duodenalis infection in Sakiz lambs

et al. 2014

View full text Add to dashboard Cite

Objective. The purposes of this study were to determine whether secnidazole administered at a single dose of 10 mg/kg, orally, lessens or eliminates Giardia cyst shedding, and to validate the benefit of secnidazole treatment on clinical signs and faecal consistency in lambs naturally infected with Giardia duodenalis. Materials and methods. To this extent weaned 12 weeks of age lambs were selected and randomly assigned into two groups based on placebo (group C, n=7 untreated control group) or treatment (group S, n=10 lambs treated with a single dose of secnidazole at 10 mg/kg). Results. On days 0 and 10, before and after treatment, respectively, reduction in cyst excretion was determined. The faecal consistency and general health were recorded at each sampling day. Conclusions. During the study there was a high (99.98%) reduction in cyst excretion in the secnidazol treatment group compared to the positive control group on day 10, resulting in a significant (p<0.001) reduction, making secnidazole highly effective treatment option.Key words: Clinics, evaluation, lamb, secnidazol (Source: CAB). RESUMENObjetivo. El objetivo de este estudio fue determinar si la administración oral de una dosis única de secnidazol de 10mh/kg reduce o elimina la presencia de quistes de Giardia y validar el beneficio del tratamiento con secnidazol en los signos clínicos y la consistencia fecal de corderos infectados naturalmente con Giardia duodenalis. Materiales y métodos. Se seleccionaron corderos destetados de 12 semanas de edad que fueron asignados al azar a dos grupos con base a placebo (grupo C, n=7, grupo de control sin tratar) o tratamiento (grupo S, n=10 corderos con tratamiento de dosis única de secnidazol de 10 mg/kg). Resultados. En los días 0 y 10, antes y después del tratamiento, respectivamente, se determinó una merma en la excreción de quistes. La consistencia de la materia fecal y el estado general de salud fue registrado en cada muestreo diario. Conclusiones. Durante el estudio hubo una alta reducción en la excreción de quistes (99.98%) en el grupo tratado con secnidazol comparado con el grupo control positivo en el día 10, resultando en una disminución significativa (p<0.001), haciendo del tratamiento con secnizadol una opción altamente efectiva.

show abstract

Section: 98%unclassified

“…and has a longer terminal elimination halflife (approximately 17 to 29 hours) than commonly used drugs in this class (28,29). It is commercialized for the treatment of giardiasis in humans.…”

Section: 98%mentioning

confidence: 99%

Single dose of secnidazole treatment against naturally occuring Giardia duodenalis infection in Sakiz lambs

et al. 2014

View full text Add to dashboard Cite

show abstract

“…(Gillis and Wiseman, 1996). Secnidazole is rapidly and completely absorbed after oral administration and has a longer terminal elimination half-life (approximately 17 to 29 hours) than commonly used drugs in this class (Gillis and Wiseman, 1996;Videau et al, 1978). It is commercialized for the treatment of giardiasis in humans.…”

Section: Introductionmentioning

confidence: 99%

Secnidazol Treatment to Improve Milk Yield in Sheep with Giardiasis

Ural¹,

Ayan²,

Aysul³

et al. 2014

Atatürk Üniversitesi Vet. Bil. Derg.

View full text Add to dashboard Cite

Abstract:The purpose of this multidiciplinary (agricultural and veterinary fields) study was to assess the effect of single secnidazol treatment on milk production in dairy ewes naturally infected with Giardia duodenalis. Thirty dairy ewes with Giardiasis, were enrolled into 3 equal groups and Groups I and II were treated with secnidazole at a single dose rate of 10 mg/kg or 30 mg/kg, respectively, perorally and G III ewes were controls. Throughout the study ewes in G III remained positive for Giardiasis, with some of them showed an increase without statistical significance in cyst counts on day 10 (ranged 1300-241650) compared to the initial values (ranged between 5600-274600). The least square means and standard error of means of cyst excretion on D0 and D10 revealed that there was a significant reduction (P<0.001) in cyst reduction in GI and GII animals. Both group GI and GII ewes produced significantly more milk than group G III ones (P<0.001). The change of mean milk yield over time was statistically significant (P<0.001) among group GI and GII ewes; besides a statistically significant (P<0.001) reduction in the mean milk yield of group GIII ewes was observed. Given the efficacy of secnidazol treatment for cyst reduction and increased milk yield, it may be safely suggested that Giardiasis adversely affects the production of the infested animals.

show abstract

“…Secnidazole is rapidly absorbed after oral administration and it has a bioavailability of about 80%. 2 The major advantages of Secnidazole are as follows: 3,4 a. Secnidazole is the longest acting medicine with a half-life of 17-29 hours in the category of nitroimidazole drugs.…”

Section: Introductionmentioning

confidence: 99%

Piperine Enhances the Bioavailability of Secnidazole in Rats

Oberoi

Tatke

2017

MOJBB

View full text Add to dashboard Cite

Abbreviations: BA, bioavailability; BV, bacterial vaginosis; TLC, thin layer chromatography; HPLC, high performance liquid chromatography; LOD, limit of detection; LOQ, limit of quantification; LLOQ, lower limit of quantification; ULOQ, upper limit of quantification; QCs, quality control samples; CV, coefficient of variation; AUC, area under curve IntroductionBioavailability (BA) is defined as the rate and extent to which the active ingredient or active moiety is absorbed from a drug product and becomes available at the site of action. For drug products that are not intended to be absorbed into the bloodstream, bioavailability may be assessed by measurements intended to reflect the rate and extent to which the active ingredient or active moiety becomes available at the site of action.1 Some drugs have poor bioavailability and hence take a longer time to act. These drugs therefore do not pass the phase 1 of the clinical trials as these do not meet the necessary criteria of having the maximum bioavailability and hence show a delayed onset of action. In such cases of bioavailability issues, one of the optimal solutions can be bioenhancement of that drug with a suitable bioenhancer to augment its bioavailabilty and hence a dose reduction. There are some drugs, however, which have a moderate bioavailability but only when given in higher doses. One such drug is Secnidazole.Secnidazole is a 5-nitroimidazole. It has a spectrum of activity against anaerobic micro-organisms and it is particularly effective in the treatment of amoebiasis, giardiasis, trichomoniasis and bacterial vaginosis. Secnidazole is rapidly absorbed after oral administration and it has a bioavailability of about 80%. 2The major advantages of Secnidazole are as follows: 3,4 a. Secnidazole is the longest acting medicine with a half-life of 17-29 hours in the category of nitroimidazole drugs.b. As such, available clinical data suggest that the main place of one-dose Secnidazole is as an alternative to multiple-dose metronidazole for treatment of mild or moderate intestinal amoebiasis, particularly in rural endemic regions lacking extensive medical facilities and follow-up capability.c. Oral doses of Secnidazole have produced clinical cure and parasitological eradication in 80 to 100% of adults and children with intestinal amoebiasis, mostly of mild or moderate severity.d. It has a broad spectrum of activity against anaerobic bacteria as compared to other drugs in the same class.In patients with intestinal amoebiasis or giardiasis, clinical or parasistological cure rates of 80 to 100% are achieved after treatment with a 2g dose of Secnidazole. This high dose of Secnidazole causes a lot of side effects even with a single dose. The symptomatic side effects produced by Secnidazole include dizziness, abdominal pain, urticaria, glossitis, stomatitis, taste disturbances, paresthesias. There are cases where the therapy has been withdrawn after a single administration due to these effects. If they become severe, they can be treated symptomatically. 5 The severe o...

show abstract

Secnidazole. A 5-nitroimidazole derivative with a long half-life.

Cited by 24 publications

References 11 publications

Single dose of secnidazole treatment against naturally occuring Giardia duodenalis infection in Sakiz lambs

Single dose of secnidazole treatment against naturally occuring Giardia duodenalis infection in Sakiz lambs

Secnidazol Treatment to Improve Milk Yield in Sheep with Giardiasis

Piperine Enhances the Bioavailability of Secnidazole in Rats

Contact Info

Product

Resources

About